Blood marker may uncover fracture risk hidden from bone scans

NCT ID NCT07677072

Recruiting now Knowledge-focused Sponsor: Kanuni Sultan Suleyman Training and Research Hospital Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study investigates whether a protein called lumican, found in the blood, can identify postmenopausal women who have fragile bones but normal bone density scans. About 100 women will have their bone density, muscle strength, and blood lumican levels measured. The goal is to see if lumican levels can reveal a hidden fragility that standard tests miss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple blood test that better identifies women at risk of fractures, beyond what bone density scans show.
What could go wrong: This is an early observational study with only 98 participants, so results may not apply to all women. Lumican levels may not reliably predict fracture risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FRAGILITY FRACTURES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Frailty osteoporosis postmenopausal osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FRAGILITY FRACTURES FRAILTY OSTEOPOROSIS POSTMENOPAUSAL OSTEOPOROSIS

Contacts and locations

Locations

Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey
RECRUITING

Küçükçekmece, Istanbul, 34303, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.